Combination therapy for maximal myocardial infarct size reduction.

Area of Science:

• Cardiovascular Research
• Ischemia-Reperfusion Injury
• Cardioprotection

Background:

• Myocardial infarct size is a critical determinant of heart failure after myocardial infarction.
• Individual therapies like cariporide, hypothermia, and ischemic preconditioning show promise in reducing infarct size.
• Optimizing infarct size reduction requires investigating synergistic effects of combined therapies.

Purpose of the Study:

• To evaluate the efficacy of a combined therapy (cariporide, regional hypothermia, ischemic preconditioning - CHIP) in reducing myocardial infarct size.
• To determine if CHIP optimizes infarct size reduction compared to individual interventions.
• To assess the protective effects of CHIP under different durations of coronary artery occlusion.

Main Methods:

• Rabbits underwent 30 or 90 minutes of coronary artery occlusion followed by reperfusion.
• Treated groups received cariporide, ischemic preconditioning, and mild regional hypothermia (CHIP).
• Control groups received saline and a waiting period; infarct size and risk zone were measured.

Main Results:

• In the 30-minute occlusion model, CHIP reduced infarct size to 4% of the risk zone (91% reduction vs. control).
• In the 90-minute occlusion model, CHIP reduced infarct size to 34% of the risk zone (55% reduction vs. control).
• Risk zone size was comparable between CHIP and control groups, indicating CHIP's specific effect on infarct size.

Conclusions:

• The combined therapy (CHIP) provides extraordinary cardioprotection against ischemia/reperfusion injury.
• CHIP significantly reduces myocardial infarct size, outperforming previously observed effects of single interventions.
• This therapeutic approach holds potential for mitigating myocardial damage even in prolonged ischemic events.